Global Health Limited · NSE:MEDANTA
Global Health — Q1 FY2027 Earnings Presentation
33 slides from Global Health's earnings presentation, Jul 30, 2026
Slide 1: Cover letter to stock exchanges
Limited July 30, 2026 Ref:- GHL/2026-27/EXCH/36 The General Manager The Manager Dept. of Corporate Services Listing Department BSE Limited, National Stock Exchange of India Limited P J Towers, Dalal Street, Exchange Plaza, C-1, Block G, Mumbai - 400 001 Bandra Kurla Complex, Bandra (E), Mumbai - 400
Slide 2: Investor Presentation Q1 FY2027
GLOBAL HEALTH LIMITED Dedicated to Life Investor Presentation Q1 FY2027 5 30th July, 2026 1
Slide 3: Disclaimer
Disclaimer I • This presentation, apart from historical information, contains some "forward-looking statements" including those describing the Company’s strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertain
Slide 4: Contents
Contents 01 Q1 FY2027 Performance Update 02 Project Update and Capex Plan 03 Medanta’s Journey, Purpose and Model of Healthcare 04 Annexures 3
Slide 5: Q1 FY2027 Performance Update
01 Q1 FY2027 Performance Update 4
Slide 6: Q1 FY2027 performance summary
Q1 FY2027 performance summary Revenue Growth of 26% y-o-y and EBITDA ex Noida growth of 24% y-o-y; Growth led by patient volumes Total Income1 EBITDA3 and Margins Profit after Tax and Margins EBITDA2 ex Noida Reported EBITDA INR 3,201 million INR 3,153 million INR 1,573 million INR 13,262 million Ma
Slide 7: Q1 FY2027 performance summary
~ Q1 FY2027 performance summary ~ ~ Revenue growth of 26% y-o-y, primarily led by increase in patient volumes and realization ~ ~ • I Highest ever quarterly total income of INR 13,262 million; growth of 26.2% y-o-y ~ I EBITDA (ex-Noida) grew 23.9 % y-o-y to INR 3,201 with improved margins of 25.8% i
Slide 8: Q1 FY2027 clinical achievements
Q1 FY2027 clinical achievements Continuing the legacy of clinical excellence I A 45-year-old critically ill lung adenocarcinoma patient with complete left lung collapse and ventilator-dependent respiratory failure was • successfully treated at Medanta Gurugram using VV-ECMO-supported therapeutic bro
Slide 9: Q1 FY2027 Business Update
Q1 FY2027 Business Update Strengthening the core and building strong pipeline for growth Capacity Expansion New Medical Equipment Deployed in Q1 FY27 Noida: 51 beds added on 9th Floor A-Wing Lucknow: 21 beds added on the 9th floor of Tower A Ranchi: Launched Surgical Oncology services Indore
Slide 10: Medanta Noida: Scaling Operations and Strengthening Clinical Capabilities
Medanta Noida: Scaling Operations and Strengthening Clinical Capabilities Continued ramp-up in patient volumes, clinical programs, and specialty services Medanta Noida Overview Key metrics 30 Sep 2025 31 Dec 2025 31 Mar 2026 30 June 2026 550+ 433 Total Census Bed 141 231 274 323 Planned beds capacit
Slide 11: Medanta Noida: Fully Operational with 433 beds
Medanta Noida: Fully Operational with 433 beds Noida operations gaining momentum, substantial reduction in EBITDA losses in Q1FY27 Total Income (INR million) EBITDA1 (INR million) 855 -30 -49 525 343 -197 -236 39 -320 0 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27
Slide 12: Key operating metrics: Revenue and profitability
Key operating metrics: Revenue and profitability Strong start to FY2027; Revenue growth of 26% with EBITDA growth (including Noida EBITDA loss) at 24% Total Income (INR million) .-----~+26.2% --------. 11,958 12,407 . 13,262 EBITDA1 (INR million and margin %) +23.5% 3,201 3,153 10,513 2,906 2,553 Q1
Slide 13: Key operating metrics: Volumes, occupancies, ALOS
Key operating metrics: Volumes, occupancies, ALOS Growth driven by in-patient volume growth of 28% y-o-y; Occupancy at 63% on the increased bed capacity Average census and occupied beds ALOS (days) +21.1% -5.2% .----------1 C)1-------,l +22.1% 3.03 3.06 2.87 2,950 3,037 2,487 1,795 1,902 1,571 Q1 FY
Slide 14: Key operating metrics: ARPOB and revenue mix
Key operating metrics: ARPOB and revenue mix ARPOB growth driven by improvement in ALOS and change in specialty mix ARPOB1 (INR) ARPP1 (INR) 201,795 204,034 201,891 +5.5% ,-------- -,C)-----, • 66,584 66,687 70,244 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 IPD Revenue mix by payor category2 Do
Slide 15: Diverse revenue mix
Diverse revenue1 mix Significant contribution from complex specialties Heart 21.0% 22.0% 20.7% Cancer 14.2% 13.4% 13.5% Digestive 11.2% 10.9% 11.0% Neuro 11.3% 11.2% 11.2% Kidney & Urology 7.6% 7.8% 8.2% Internal Medicine 5.8% 6.0% 5.5% Ortho 5.7% 5.4% 6.7% Liver Transplant 3.0% 2.7% 2.7% Others Spe
Slide 16: Cluster 1 hospitals - Gurugram, Indore and Ranchi
Cluster 1 hospitals - Gurugram, Indore and Ranchi Consistent Growth with Improved Margins Total Income (INR million) EBITDA (INR million and margin %) ARPP (INR) +10.1% +13.3% 220,037 219,623 7,715 1,858 7,006 1,640 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 23.4% 24.1% In-patient Volume (count
Slide 17: Cluster 2 hospitals – Lucknow, Patna and Noida
Cluster 2 hospitals – Lucknow, Patna and Noida Strong Revenue and EBITDA Growth Continues Total Income (INR million) EBITDA (INR million and margin %) ARPP (INR) +28.2% +54.8% +40.2% +35.0% +4.6% 4,983 1,321 1,272 177,668 182,407 4,128 174,342 3,219 942 Q1 FY26 Q1 FY27 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY2
Slide 18: Project Update and Capex Plan
04 Project Update and Capex Plan 17
Slide 19: On-going expansion projects
On-going expansion projects ~20% Capacity added in FY26. Planned bed capacity addition to drive sustainable growth Number of installed beds ~ 2,950 bed addition +71.0% 623 bed addition +20.5% i----------, ,-----C 490 bed addition +13.4% ~ 1 - - - - - - - - - , l - - ------C 117 ::::r 49 '~ ------r--
Slide 20: Capex plan next 5 years
Capex plan next 5 years Total capex of ~INR 48,500 million planned for next 5 years 2,082 399 3,000 5,900 9,040 5,833 48,582 43,500 12,380 6,000 3,425 523 Maintenance Lucknow, South Mumbai Pitampura, Guwahati Varanasi Indore Medical Guest House Total Capex Capex for 3 Patna, Delhi- DLF Delhi Cancer
Slide 21: Medanta's Journey, Purpose and Model of Healthcare
Medanta’s Journey, Purpose and Model of 05 Healthcare 20
Slide 22: Medanta was founded to bring a new type of healthcare to India
Medanta was founded to bring a new type of healthcare to India… … the human side of healthcare Healthcare is never only about science. It is also about the art of medicine – the human connection, putting the patient first, collaboration, the personal acts of empathy and the values that guide our dec
Slide 23: Growth from a single flagship hospital in Gurgaon
Growth from a single flagship hospital in Gurgaon… …to a network of 6 high quality hospitals across north India FY2026 MEDANTA 2025 HOSPITAL MEDANTA HOSPITAL NOIDA 2021 Ranchi Unit 2 550 Beds 2019 JAI PRABHA MEDANTA 433 currently 110 Beds operational MEDANTA SPECIALTY HOSPITAL Commenced including 98
Slide 24: From our flagship Medicity campus we have grown to 3,737 beds across 6 cities
~ From our flagship Medicity campus in Gurgaon, we have grown to 3,737 beds d l\!,,,, meoa ma ~ across 6 cities =mF ~ Largest private hospital beds in operation under one roof in Delhi (NCR), Uttar Pradesh and Bihar ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ Gurgaon LUCKNOW PATNA ~ 1,440 beds; 316 ICU beds 778 beds; 211 I
Slide 25: One of the largest private hospital chains in North and East India
One of the largest private hospital chains in North and East India Serving over 400 million people in the States with Medanta facilities Gurugram; Largest single location private hospital in with operational Delhi; ~1,150 bed addition bed capacity of 1,440 Our Network planned with 750 beds in Pitamp
Slide 26: Our Mission and Values
Our Mission and Values Embracing a new era and redefining our purpose Core Values Patient centric care: Foster a culture where every one of us is MISSION committed to care for patients and their caregivers Our mission is to deliver world class, patient centric, ef!: Leadership and quality: Commit to
Slide 27: The Medanta Model of Healthcare
The Medanta Model of Healthcare Delivering the highest quality of medicine with care and compassion Exceptional clinical talent What it means for patients and caregivers? • Super specialized doctors provide the highest quality of care through a team based integrated approach Trust based • A safe and
Slide 28: Medanta is well placed to deliver sustainable growth
Medanta is well placed to deliver sustainable growth… …while maintaining its core values of patient centric care and clinical leadership and quality CONTINUITY OF CARE TECHNOLOGY Extend clinical THOUGHT ADVANCEMENT services outside LEADERSHIP Use technology to improve hospital and across ENHANCE Bui
Slide 29: Annexures
06 Annexures 28
Slide 30: Annexure: Profit and Loss Statement
Annexure: Profit and Loss Statement Quarter INR million Q1FY2026 Q4FY2026 Q1FY2027 Y-o-Y Growth % Q-o-Q Growth % Revenue from operations 10,308 11,590 13,041 I 26.5% 12.5% Other income 205 367 222 I 8.3% (39.7)% Total income 10,513 11,958 13,262 I 26.2% 10.9% Cost of materials consumed Employee bene
Slide 31: Annexure: Operational Parameters
Annexure: Operational Parameters Quarter Key metrics Q1 FY26 Q4 FY26 Q1 FY27 Y-o-Y Growth % Total Beds 3,062 3,665 3,737 22.0% Census Beds 2,487 2,950 3,037 22.1% I 1,61,429 Occupied Bed Days 142,898 1,73,064 I_ 21.1% _ 60.9% 62.6% Occupancy Rate % 63.2% I _(53)_bps 1 66,687 ARPOB (INR) 66,584 70,24
Slide 32: Annexure: Abbreviations and Definitions
Annexure: Abbreviations and Definitions Abbreviations INR : Indian Rupee NABH : National Accreditation Board for Hospitals & Healthcare Providers NABL : National Accreditation Board for Testing and Calibration Laboratories JCI : Joint Commission International OPD : Out-Patient Department
Slide 33: Contact us
Contact us About Medanta Contact Details Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and Gaurav Chugh Bhushan Khandelwal cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan Head Investor Relations Investor Relations and the Padma Shri, the third- and fourth-hi